HESTERBIO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Hester Biosciences hits over 1-mth low on Q4 profit fall
** Shares of poultry and animal healthcare co Hester Biosciences Ltd HEST.NS fall as much as 8.1% to 1,686 rupees, lowest since April 12
** Steepest intraday pct decline since March 13
** Co reports 41.3% drop in Q4 profit to 45.3 mln rupees ($553,925.17)
** Revenue from co's poultry healthcare division, which accounts for 60.2% of standalone revenue, fell 8.4%
** The poultry industry continues to be under pressure due to high feed costs and low product realisations - HEST said in a statement
** Over 16,000 shares change hands as of 1:31 pm IST, 3.5X the 30-day moving average
** Stock down 2.4% YTD as of last close
($1 = 81.7800 Indian rupees)
(Reporting by Varun Vyas in Bengaluru)
** Shares of poultry and animal healthcare co Hester Biosciences Ltd HEST.NS fall as much as 8.1% to 1,686 rupees, lowest since April 12
** Steepest intraday pct decline since March 13
** Co reports 41.3% drop in Q4 profit to 45.3 mln rupees ($553,925.17)
** Revenue from co's poultry healthcare division, which accounts for 60.2% of standalone revenue, fell 8.4%
** The poultry industry continues to be under pressure due to high feed costs and low product realisations - HEST said in a statement
** Over 16,000 shares change hands as of 1:31 pm IST, 3.5X the 30-day moving average
** Stock down 2.4% YTD as of last close
($1 = 81.7800 Indian rupees)
(Reporting by Varun Vyas in Bengaluru)
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Hester Biosciences do?
Hester Biosciences Limited, a premier animal healthcare company in India known for poultry vaccines. Established in 1987, it has become a top global manufacturer with Asia's largest animal biological manufacturing unit in Ahmedabad.
Who are the competitors of Hester Biosciences?
Hester Biosciences major competitors are Bajaj Healthcare, Themis Medicare, NGL Fine-Chem, Kopran, Shree Ganesh Remed., Everest Organics, Haleos Labs. Market Cap of Hester Biosciences is ₹1,363 Crs. While the median market cap of its peers are ₹800 Crs.
Is Hester Biosciences financially stable compared to its competitors?
Hester Biosciences seems to be less financially stable compared to its competitors. Altman Z score of Hester Biosciences is 3.87 and is ranked 5 out of its 8 competitors.
Does Hester Biosciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Hester Biosciences latest dividend payout ratio is 21.66% and 3yr average dividend payout ratio is 24.75%
How has Hester Biosciences allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Hester Biosciences balance sheet?
Balance sheet of Hester Biosciences is strong. But short term working capital might become an issue for this company.
Is the profitablity of Hester Biosciences improving?
Yes, profit is increasing. The profit of Hester Biosciences is ₹34.35 Crs for TTM, ₹27.49 Crs for Mar 2025 and ₹18.89 Crs for Mar 2024.
Is the debt of Hester Biosciences increasing or decreasing?
The net debt of Hester Biosciences is decreasing. Latest net debt of Hester Biosciences is ₹194 Crs as of Mar-25. This is less than Mar-24 when it was ₹210 Crs.
Is Hester Biosciences stock expensive?
Hester Biosciences is not expensive. Latest PE of Hester Biosciences is 36.25, while 3 year average PE is 60.11. Also latest EV/EBITDA of Hester Biosciences is 23.61 while 3yr average is 33.52.
Has the share price of Hester Biosciences grown faster than its competition?
Hester Biosciences has given lower returns compared to its competitors. Hester Biosciences has grown at ~3.7% over the last 8yrs while peers have grown at a median rate of 13.4%
Is the promoter bullish about Hester Biosciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Hester Biosciences is 53.73% and last quarter promoter holding is 53.73%.
Are mutual funds buying/selling Hester Biosciences?
There is Insufficient data to gauge this.
